@article{64b9e6ab38a841a7b277cdcbf4af9f96,
title = "Neurophysiological correlates of non-motor symptoms in late premanifest and early-stage manifest huntington's disease",
abstract = "Objective: To find sensitive neurophysiological correlates of non-motor symptoms in Huntington's disease (HD), which are essential for the development and assessment of novel treatments. Methods: We used resting state EEG to examine differences in oscillatory activity (analysing the isolated periodic as well as the complete EEG signal) and functional connectivity in 22 late premanifest and early stage people with HD and 20 neurotypical controls. We then assessed the correlations between these neurophysiological markers and clinical measures of apathy and processing speed. Results: Significantly lower theta and greater delta resting state power was seen in the HD group, as well as significantly greater delta connectivity. There was a significant positive correlation between theta power and processing speed, however there were no associations between the neurophysiological and apathy measures. Conclusions: We speculate that these changes in oscillatory power and connectivity reflect ongoing, frontally concentrated degenerative and compensatory processes associated with HD. Significance: Our findings support the potential utility of quantitative EEG as a proximate marker of processing speed, but not apathy in HD.",
keywords = "Apathy, Electroencephalography (EEG), Functional connectivity, Huntington's disease (HD), Processing speed",
author = "Davis, {Marie Claire} and Hill, {Aron T.} and Fitzgerald, {Paul B.} and Bailey, {Neil W.} and Stout, {Julie C.} and Hoy, {Kate E.}",
note = "Funding Information: MCD was supported by the Research Training Program Stipend and a Monash Graduate Excellence Scholarship. KEH was supported by National Health and Medical Research Council (NHMRC) Fellowships (1082894 and 1135558). PBF was supported by an Investigator Fellowship from the NHMRC (1193596). ATH was supported by an Alfred Deakin Postdoctoral Research Fellowship. We gratefully acknowledge the time, involvement, and feedback from the participants. This research would not have been possible without them. We also acknowledge the assistance with participant recruitment provided by the Statewide Progressive Neurological Disease Service at Calvary Health Care Bethlehem. KEH is a founder of Resonance Therapeutics. PBF has received equipment for research from MagVenture A/S, Nexstim, Neuronetics and Brainsway Ltd and funding for research from Neuronetics. PBF is a founder of TMS Clinics Australia and Resonance Therapeutics. JCS is founder and a director of Zindametrix which provides cognitive assessment services in HD clinical trials, and Stout Neuropsych, which provides consultancy services for pharmaceutical companies. MCD, ATH, and NWB have no biomedical financial interests or potential conflicts of interest to report. Funding Information: MCD was supported by the Research Training Program Stipend and a Monash Graduate Excellence Scholarship. KEH was supported by National Health and Medical Research Council (NHMRC) Fellowships (1082894 and 1135558). PBF was supported by an Investigator Fellowship from the NHMRC (1193596). ATH was supported by an Alfred Deakin Postdoctoral Research Fellowship. We gratefully acknowledge the time, involvement, and feedback from the participants. This research would not have been possible without them. We also acknowledge the assistance with participant recruitment provided by the Statewide Progressive Neurological Disease Service at Calvary Health Care Bethlehem. Publisher Copyright: {\textcopyright} 2023 International Federation of Clinical Neurophysiology",
year = "2023",
month = sep,
doi = "10.1016/j.clinph.2023.06.021",
language = "English",
volume = "153",
pages = "166--176",
journal = "Clinical Neurophysiology",
issn = "1388-2457",
publisher = "Elsevier",
}